Medicenna Receives Regulatory Clearance to Expand the Phase 1/2 ABILITY Study of MDNA11 to Canada
December 17, 2021 07:00 ET
|
Medicenna Therapeutics Corp.
-- ABILITY Study is currently ongoing at clinical trial sites in Australia and previously received FDA clearance to expand to sites in the United States -- Preliminary update on safety and PK/PD data...
Medicenna Receives Award for Excellence in Clinical Trials in Connection with an Upcoming Presentation at the 26th Annual Meeting of the Society for Neuro-Oncology
November 18, 2021 07:00 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced...
Medicenna Reports Second Quarter Fiscal 2022 Financial Results and Operational Highlights
November 12, 2021 07:00 ET
|
Medicenna Therapeutics Corp.
-- Phase 1/2 ABILITY Study of MDNA11 on track for preliminary data updates in calendar 2021 and mid-calendar 2022 -- Management hosting conference call and webcast today at 8:30 am ET TORONTO and...
Medicenna Therapeutics to Present at Stifel’s Virtual Healthcare Conference
November 09, 2021 07:00 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced...
Medicenna Therapeutics to Announce Second Quarter 2022 Financial Results and Operational Highlights on Friday, November 12, 2021
November 04, 2021 08:00 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced...
Medicenna Announces FDA Clearance of IND to Expand the Phase 1/2 ABILITY Study of MDNA11 to the United States
October 27, 2021 08:00 ET
|
Medicenna Therapeutics Corp.
-- ABILITY Study is currently ongoing at clinical trial sites in Australia -- Preliminary update on safety, PK/PD, and biomarker data expected by year-end 2021 -- Initial efficacy data update...
Medicenna Presents MDNA11 Data from IND-Enabling Studies at the AACR-NCI-EORTC Conference
October 07, 2021 09:05 ET
|
Medicenna Therapeutics Corp.
-- MDNA11 preferentially induced durable proliferation and expansion of anti-cancer immune cells with limited stimulation of pro-tumor Treg cells in non-human primates (NHP) -- MDNA11 administration...
Medicenna Appoints Dr. John H. Sampson to its Board of Directors
September 23, 2021 16:30 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today...
Medicenna Presenting at Next-Gen Cytokine Therapeutics Summit
September 22, 2021 08:00 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today...
Medicenna Announces Issuance of U.S. Patent Providing Added Intellectual Property Protection for its MDNA11 Program
September 20, 2021 08:00 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today...